Another interesting fact that Gleevec turned novartis around. but that patent expires soon. There was a patent battle they lost in India w.r.t. "evergreening" gleevec i.e. a small change in the drug that would help them repatent it.

Shockingly they wanted to keep the price tag of ~3000$ you quoted which is > 95% of the population's gross annual income.